Keyword: Kadcyla

With a new FDA nod in postsurgery patients—and Herceptin biosimilars looming—Roche's Kadcyla has more space to run.

Last July, Roche put a halt on U.S. price hikes. But that didn't stop five of its products from topping analysts' estimates by double digits in Q1.

Roche could use a speedy Kadcyla label expansion to help quiet concerns about mounting biosimilar competition to its aging blockbusters.

With biosim rivals looming, Roche will need its newer meds to step up, and Wednesday's Kadcyla data could give its breast cancer franchise a boost.

Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.

Roche is teeing up a new use for its breast cancer drug Kadcyla, hoping to gin up sales as Herceptin biosimilars hurtle toward the U.S. market.

Cost watchdogs in England and pharma don't always agree, but the sides are celebrating two new deals on Merck KGaA's Mavenclad and Roche's Perjeta.

Roche has sealed a deal to provide Gazyvaro to U.K. patients through the revamped Cancer Drugs Fund.

After years of back and forth, U.K. drug cost watchdog NICE said today it has deemed Roche's breast cancer drug Kadcyla as cost effective.

Swiss cancer major Roche has delivered a solid set of financials this morning as the drugmaker looks toward a strong 2016 with a host of new approvals on the horizon.